ArrowMark Colorado Holdings LLC Lowers Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

ArrowMark Colorado Holdings LLC cut its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 0.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,092 shares of the company’s stock after selling 1,808 shares during the quarter. ArrowMark Colorado Holdings LLC owned 0.42% of Structure Therapeutics worth $10,582,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of GPCR. Sandia Investment Management LP acquired a new position in Structure Therapeutics during the 2nd quarter worth $39,000. Assetmark Inc. boosted its stake in shares of Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after buying an additional 719 shares during the period. Quarry LP acquired a new position in shares of Structure Therapeutics during the second quarter worth about $79,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC purchased a new stake in shares of Structure Therapeutics during the third quarter worth approximately $202,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GPCR has been the topic of a number of analyst reports. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective on the stock. JMP Securities decreased their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $86.80.

Structure Therapeutics Trading Up 2.4 %

Shares of NASDAQ GPCR opened at $33.94 on Tuesday. Structure Therapeutics Inc. has a twelve month low of $26.61 and a twelve month high of $66.38. The stock has a 50 day moving average of $38.04 and a two-hundred day moving average of $39.44.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.